CD3/CD19 Depleted or CD3 Depleted/CD56 Selected Haploid Donor Natural Killer Cell Treatment in Older AML in First Complete Remission

NCT01639456 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped study was abandoned and a new study was written to replace this one

Conditions

Acute Myelogenous Leukemia

Interventions

BIOLOGICAL: CD3-/CD19- natural killer cells
BIOLOGICAL: CD3-CD56+ natural killer cells
DEVICE: CliniMACS® CD3 and CD19 Reagent System
DEVICE: CliniMACS® CD56 Reagent System
DRUG: Cyclophosphamide
DRUG: Fludarabine
DRUG: Aldesleukin

Sponsor

Masonic Cancer Center, University of Minnesota

Collaborators

[object Object]